Volume 7, Issue 3 (Journal of Research in Dental & Maxillofacial Sciences Summer 2022)                   J Res Dent Maxillofac Sci 2022, 7(3): 162-167 | Back to browse issues page

Ethics code: IR.SUMS.REC.1396.S452


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

lavaee F, Vahdatifar B, Afroozi B, Tavakoli F. Epidemiologic Study of Patients with Chronic Vesiculobullous Lesions. J Res Dent Maxillofac Sci. 2022; 7 (3) :162-167
URL: http://jrdms.dentaliau.ac.ir/article-1-357-en.html
1- Student Research Committee, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
2- School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran
3- Oral and Maxillofacial Medicine Department, School of Dentistry, Yasuj University of Medical Sciences, Yasuj, Iran
4- Oral and Dental Disease Research Center, Oral and Maxillofacial Medicine Department, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran , ktavakoli766@gmail.com
Abstract:   (63 Views)
Background and Aim: Vesiculobullous diseases (VBDs) are characterized by the formation of vesicles or bullae. The aim of this study was to perform an epidemiological survey on patients with chronic VBDs referred to Shiraz Dental School during 2006-2016.   
Materials and Methods: In this retrospective cross-sectional study, epidemiological data (age, sex, prevalence, involvement location, prescribed medication, and underlying diseases) of patients diagnosed with VBDs were collected. The relationship between the epidemiological factors and the occurrence of VBDs was analyzed. SPSS version 18 was used to analyze the data by the Chi-square test and Spearman’s correlation test.
Results: Totally, 120 patients were evaluated; out of which, 88.3% had pemphigus vulgaris (PV), 4.2% had bullous pemphigoid (BP), 6.8% had mucous membrane pemphigoid (MMP), and 0.1% had pemphigus herpetiformis (PH). Most patients were females (68.3%) and 31.7% were males. The mean age of patients was 43.14±11.41 years. The mucosal and cutaneous involvement in PV patients was as follows: 31.13% had mucosal, 0.94% had cutaneous, 37.73% had both mucosal and cutaneous, and 30.18% had mucosal-cutaneous involvement associated with involvement of other organs. Prednisolone was the first-line treatment in all patients. There was a significant correlation between age and incidence of VBDs in patients (P=0.030).
Conclusion: Our findings indicated that the epidemiological properties of VBDs in our study were similar to those in other countries. However, PV was the most common VBD followed by BP.
Full-Text [PDF 716 kb]   (32 Downloads) |   |   Full-Text (HTML)  (13 Views)  
Type of Study: Original article | Subject: Oral medicine

References
1. Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients. An Bras Dermatol. 2014 Mar-Apr; 89 (2):274-8. [DOI:10.1590/abd1806-4841.20142516] [PMID] [PMCID]
2. Mortazavi H, Amirzargar AA, Esmaili N, Toofan H, Ehsani AH, Hosseini SH, Rezaei N. Association of human leukocyte antigen class I antigens in Iranian patients with pemphigus vulgaris. J Dermatol. 2013 Apr;40(4):244-8. [DOI:10.1111/1346-8138.12071] [PMID]
3. Patel F, Wilken R, Patel FB, Sultani H, Bustos I, Duong C, Zone JJ, Raychaudhuri SP, Maverakis E. Pathophysiology of Autoimmune Bullous Diseases: Nature Versus Nurture. Indian J Dermatol. 2017 May-Jun;62(3):262-7.
4. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009 Jan 21;(1): CD006263. [DOI:10.1002/14651858.CD006263.pub2]
5. Jaafari-Ashkavandi Z, Mardani M, Pardis S, Amanpour S. Oral mucocutaneous diseases: clinicopathologic analysis and malignant transformation. J Craniofac Surg. 2011 May; 22(3):949-51. [DOI:10.1097/SCS.0b013e31820fe1f0] [PMID]
6. Marazza G, Pham HC, Schärer L, Pedrazzetti PP, HunzikerT, Trüeb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L; Autoimmune bullous disease Swiss study group. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009Oct;161(4):861-8. [DOI:10.1111/j.1365-2133.2009.09300.x] [PMID]
7. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity. 2012 Feb;45(1):7-35. [DOI:10.3109/08916934.2011.606444] [PMID] [PMCID]
8. Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, Ciuce D, Sitaru C. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010 Jul;49(7):768-74. [DOI:10.1111/j.1365-4632.2009.04345.x] [PMID]
9. Jowkar F, Sadati MS, Tavana S, Agah MA. Epidemiology of autoimmune bullous diseases and therapeutic modalities during a 10 year period in Iran. Acta Dermatovenerol Croat. 2014;22(4):246-9.
10. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clinics in Dermatology. 2011;29(4):432-6. [DOI:10.1016/j.clindermatol.2011.01.013] [PMID]
11. Scully C, Lo Muzio L. Oral mucosal diseases: mucous membrane pemphigoid. Br J Oral Maxillofac Surg. 2008 Jul; 46(5):358-66. [DOI:10.1016/j.bjoms.2007.07.200] [PMID]
12. Daneshpazhooh M, Chams-Davatchi C, Payandemehr P, Nassiri S, Valikhani M, Safai-Naraghi Z. Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Int J Dermatol. 2012 Jan;51(1):35-41. [DOI:10.1111/j.1365-4632.2011.04946.x] [PMID]
13. Sobhan M, Farshchian M, Tamimi M. Spectrum of autoimmune vesiculobullous diseases in Iran: a 13-year retrospective study. Clin Cosmet Investig Dermatol. 2016 Jan 11;9:15-20. [DOI:10.2147/CCID.S97214] [PMID] [PMCID]
14. Esmaili N, Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Toosi S, Karimi A, Mortazavi H. Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris. Arch Iran Med. 2014 Sep;17(9):626-8.
15. Salmanpour R, Shahkar H, Namazi MR, Rahman-Shenas MR. Epidemiology of pemphigus in south-western Iran: a 10-year retrospective study (1991-2000). Int J Dermatol. 2006 Feb;45(2):103-5. [DOI:10.1111/j.1365-4632.2004.02374.x] [PMID]
16. Bastuji-Garin S, Souissi R, Blum L, Turki H, Nouira R, Jomaa B, Zahaf A, Ben Osman A, Mokhtar I, Fazaa B, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol. 1995 Feb;104(2):302-5. [DOI:10.1111/1523-1747.ep12612836] [PMID]
17. Mahé A, Flageul B, Cissé I, Kéita S, Bobin P. Pemphigus in Mali: a study of 30 cases. Br J Dermatol. 1996 Jan; 134(1): 114-9. [DOI:10.1111/j.1365-2133.1996.tb07848.x] [PMID]
18. Abrèu-Velez AM, Hashimoto T, Bollag WB, Tobón Arroyave S, Abrèu-Velez CE, Londoño ML, Montoya F,Beutner EH. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol. 2003 Oct; 49(4): 599-608. [DOI:10.1067/S0190-9622(03)00851-X]
19. Bertram F, Bröcker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009 May;7(5):434-40. [DOI:10.1111/j.1610-0387.2008.06976.x] [PMID]
20. Nanda A, Dvorak R, Al-Saeed K, Al-Sabah H, Alsaleh QA. Spectrum of autoimmune bullous diseases in Kuwait. Int J Dermatol. 2004 Dec;43(12):876-81. [DOI:10.1111/j.1365-4632.2004.02292.x] [PMID]
21. Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: A population-based study on incidence. J Am Acad Dermatol. 1999 Aug;41(2 Pt 1):266-8. [DOI:10.1016/S0190-9622(99)70061-7]
22. Tallab T, Joharji H, Bahamdan K, Karkashan E, Mourad M, Ibrahim K. The incidence of pemphigus in the southern region of Saudi Arabia. Int J Dermatol. 2001 Sep;40(9):570-2. [DOI:10.1046/j.1365-4362.2001.01247.x] [PMID]
23. Amin MN, Islam AZ. Clinical, histologic and immunologic features of pemphigus in Bangladesh. Int J Dermatol. 2006 Nov;45(11):1317-8. [DOI:10.1111/j.1365-4632.2006.02942.x] [PMID]
24. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, Barzegari M, Akhiani M, Ghodsi Z, Mortazavi H, Naraghi Z. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005 Jun;44(6):470-6. [DOI:10.1111/j.1365-4632.2004.02501.x] [PMID]
25. Zaraa I, Sellami A, Bouguerra C, Sellami M, Chelly I, Zitouna M, et al. Pemphigus vegetans: a clinical, histological, immunopathological and prognostic study. J Eur Acad Dermatol Venereol. 2011;25(10):1160-7.
26. Farshchian M, Pilehvar M. Evaluation of Characteristics of Pemphigus Patients Hospitalized in the Dermatology Ward of Sina Hospital Hamadan - Iran During 1992-1995. Avicenna J Clin Med. 2001; 8 (2):24-28.
27. Sadr Eshkevari S, Maboudi A, Akbari Dastak E, Golchai J, Shams Guilani J, Dorjani A, Alizadeh N, et al. Pemphigus in Guilan: Clinical and epidemiologic features of 126 hospitalized patients. Iranian Journal of Dermatology. 2005; 8(2): 104-9.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Research in Dental and Maxillofacial Sciences

Designed & Developed by : Yektaweb